30 October 2021 - Late treatment study
miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin
et al., Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329 (Peer Reviewed)
Prospective 320 hospitalized moderate COVID-19+ patients in Egypt, 160 treated with ivermectin, showing lower mortality, improved recovery, and decreased cytokine expression with treatment. All patients were treated with HCQ. 7890/26-8-2020.
|
risk of death, 80.0% lower, RR 0.20, p = 0.50, treatment 0 of 160 (0.0%), control 2 of 160 (1.2%), NNT 80, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of progression, 55.6% lower, RR 0.44, p = 0.06, treatment 8 of 160 (5.0%), control 18 of 160 (11.2%), NNT 16, 2 weeks, including deaths.
|
|
risk of no recovery, 33.4% lower, RR 0.67, p = 0.27, treatment 14 of 145 (9.7%), control 20 of 138 (14.5%), NNT 21, 4 weeks, more patients were lost to followup in the control group.
|
|
time to viral-, 27.3% lower, relative time 0.73, p = 0.01, treatment 160, control 160.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Rezk et al., 10/30/2021, prospective, Egypt, Africa, peer-reviewed, 4 authors, dosage 36mg days 1, 3, 6.
Contact:
nonnarezk@yahoo.com.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.